BOSTON ( TheStreet) -- The American Society of Clinical Oncology (ASCO) posted thousands of cancer drug research abstracts to its web site Thursday night, in advance of its closely watched annual meeting.

The ASCO annual meeting runs June 4-8 and brings together cancer drug researchers from all over the world to discuss and present new clinical data aimed at treating -- and maybe one day curing -- cancer.

The ASCO annual meeting also attracts investors in almost equal numbers because treating cancer is big business. Wall Street pays close attention because the ASCO meeting moves biotech and drug stocks, often well before the ASCO confab even gets started.

Wall Street's focus on the ASCO annual meeting kicked into another gear Thursday night with the release of the research abstracts. Previously, I assembled a list of biotech and drug stocks that will be presenting new clinical data at this year's ASCO meeting. I've now updated this list with information and data taken from the newly released research abstracts.

> > Bull or Bear? Vote in Our Poll

Flip through the list of ASCO stocks on the following pages:

Celldex Therapeutics ( CLDX)

Drug: CDX-110 (PF-04948568)

Abstract No.2014

Indication: Glioblastoma (brain tumor)

Clinical Trial: Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide in patients with glioblastoma (GBM).

Presentation Time: Saturday, June 5. Poster session.

Notes:Thursday's research abstract reports efficacy results on the first 40 patients enrolled. Twenty-eight of 40 patients, or 70%, are progression free at 5.5 months of follow up. One patient reported a serious hypersensitivity reaction to the CDX-110 injections that required discontinuation from the study. The abstract also states that an additional, placebo-controlled study of CDX-110 will likely be required.

Celldex's CDX-110, partnered with Pfizer, is engineered to activate a patient's immune system to fight cancer. Interest in so-called cancer "vaccines" is increasing as Dendreon ( DNDN) awaits FDA approval of its prostate cancer immunotherapy Provenge.

ArQule ( ARQL)

Drug:ARQ 197

Abstract No.LBA7502

Indication: Non-small cell lung cancer

Clinical Trial: Results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-negative patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Presentation Time: Saturday, June 5. Oral session.

Notes: Arqule announced top-line results from this phase II study of ARQ 197 at the end of March. ASCO did not release the research abstract for ARQ 197 Thursday night.

Delcath Systems ( DCTH)

Drug: Percutaneous Hepatic Perfusion

Abstract No. LBA8512

Indication: Liver metastases from melanoma

Clinical Trial: A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma.

Presentation Time: Saturday, June 5. Oral session.

Notes: Investors will get the first detailed look at data from the positive phase III study announced in April. ASCO did not release the PHP abstract Thursday night.

Pharmacyclics ( PCYC)

Drug: PCI-32765

Abstract No. 8012

Indication: non-Hodgkin's lymphoma

Clinical Trial: Btk inhibitor PCI-32765 monotherapy induces objective responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study.

Presentation Time: Saturday, June 5. Oral session.

Notes: Interim data from 19 of 22 patients are reported in Thursday night's ASCO abstract, with a 42% overall response rate. This includes 1 patient reporting a complete response and 7 patients with partial responses. All patients in the study were diagnosed with advanced NHL, previously treated with a median of three therapies. Phase II studies of PCI-32765 are planned.

Since December, Pharmacyclics shares have gone from $2 to $7 as the company puts a history of drug development failures behind it and builds a new research pipeline.

Bristol-Myers Squibb ( BMY)

Drug: ipilimumab

Abstract No. 4

Indication: melanoma

Clinical Trial: A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Presentation Time:Sunday, June 6. ASCO Plenary Session.

Notes:Bristol gained full ownership of ipilimumab when it acquired Medarex in 2009. ASCO did not release the research abstract Thursday night.

Celgene ( CELG)

Drug: Revlimid

Abstract No. 8017

Indication: Multiple myeloma

Clinical Trial: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma: CALGB 100104.

Presentation Time: Sunday, June 6. Oral session.

Notes:Treatment with a maintenance regimen of Revlimid resulted in a 58% reduction in the risk of tumor progression compared to placebo. The median time to progression in the placebo arm was 25.5 months, while median time to progression in the Revlimid arm has not yet been reached.

In a separate but similar study also looking at Revlimid maintenance in multiple myeloma patients, Revlimid treatment resulted in a 54% reduction in the risk of tumor progression compared to placebo.

Pfizer ( PFE)

Drug: PF-02341066

Abstract No. 3

Indication: non-small cell lung cancer

Clinical Trial: Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer.

Presentation Time: Sunday, June 6. ASCO Plenary Session.

Notes: Pfizer gets a primetime slot at ASCO to highlight its research efforts into personalized cancer drugs. ASCO did not release the abstract Thursday night.

Nektar Therapeutics ( NKTR)

Drug: NKTR-102

Abstract No. 5013

Indication: ovarian cancer

Clinical Trial: Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

Presentation Time: Sunday, June 6. Oral session.

Notes: Women treated with NKTR-102 once ever 14 days reported a 47% response rate, while women treated with NKTR-102 once ever 21 days reported a 41% response rate, according to Thursday's research abstract. These reported response rates from 71 enrolled patients are higher than interim results from the same study reported last January.

Roche/Genentech

Drug: Avastin

Abstract No. LBA1

Indication: Ovarian cancer

Clinical Trial: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Presentation Time: Sunday, June 6. ASCO Plenary Session.

Notes: Once again, Genentech and Avastin claim a covered spot on the podium during ASCO's plenary session. ASCO did not release the research abstract Thursday night.

Ziopharm Oncology ( ZIOP)

Drug: palifosfamide

Abstract No. 10004

Indication: Sarcoma

Clinical Trial: A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO).

Presentation Time: Monday, June 7. Oral session.

Notes: The combination of palifosfamide and doxorubicin demonstrates an approximate doubling in progression-free survival over doxorubicin alone (7.8 months versus 4.4 months), according to Thursday's research abstract.

Ziopharm is in the planning stages for a pivotal phase III study of palifosfamide in soft tissue sarcoma, expected to begin later this year.

Sunesis Pharmaceuticals ( SNSS)

Drug: Voreloxin

Abstract No. 5002

Indication: ovarian cancer

Clinical Trial:Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer.

Presentation Time: Monday, June 7. Oral session.

Notes: Final response rate across three different dosages of Voreloxin was 11% with a median progression-free survival of 84 days.

Sunesis will also be presenting final phase II data from a study of voreloxin in patients with acute myeloid leukemia.

Curis ( CRIS)

Drug: GDC-0449

Abstract No. 3530

Indication: colorectal cancer

Clinical Trial: Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 vs. placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).

Presentation Time: Tuesday, June 8. Poster session.

Notes:Safety data reported in the abstract was still blinded but will be presented in full detail during the ASCO meeting. GDC-0449 is partnered with Roche/Genentech.

Keryx Pharmaceuticals ( KERX)

Drug: perifosine

Abstract No. 3531

Indication: colorectal cancer

Clinical Trial: Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients with second- or third-line metastatic colorectal cancer.

Presentation Time: Tuesday, June 8. Poster session.

Notes: The final overall survival results from the phase II colon cancer study remains the same from data presented in January -- 18 months for the perifosine arm compared to 11 months for the control arm, according to the ASCO research abstract. The abstract notes that the benefit seen in the study is consistent even in a subset of patients who no longer respond to the chemo drug 5-FU. Keryx has already started a phase III study of perifosine in colorectal cancer.

-- Reported by Adam Feuerstein in Boston.
FDA Calendar
14 Biotech Stocks Facing FDA Approval

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.